Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
MALVERN, Pa., May 01, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its first quarter financial results before the market opens on May 9, 2017.
Management will conduct a conference call at 4:30 PM ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
